| Original language | English (US) |
|---|---|
| Pages (from-to) | 677-680 |
| Number of pages | 4 |
| Journal | Critical care medicine |
| Volume | 51 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2023 |
Keywords
- cerebral blood flow
- children
- head trauma
- intracranial pressure
- seizure
- spreading depolarization
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Critical care medicine, Vol. 51, No. 5, 01.05.2023, p. 677-680.
Research output: Contribution to journal › Editorial › peer-review
TY - JOUR
T1 - The Evolution of Ketamine in Severe Pediatric Traumatic Brain Injury, From Contraband to Promising Neuroprotectant?∗
AU - Kochanek, Patrick M.
AU - Herrmann, Jeremy R.
AU - Bleck, Thomas P.
N1 - Funding Information: Dr. Kochanek’s institution received funding from the National Institutes of Health (NIH) and the U.S. Army; he received funding from lectures at national meetings and/or as a guest professor at various institutions of higher education and for editing or authoring books and/or chapters; and he disclosed that he has served as an expert witness on several cases over the past 36 months and has multiple patents. Dr. Herrmann’s institution received funding from the NIH (T32 HD040686), the Safar Center for Resuscitation Research, the Zoll Foundation, and the Laerdal Foundation. Dr. Hermann received support for article research from the NIH. Dr. Bleck received funding from Marinus Pharmaceuticals and the American Board of Internal Medicine; he disclosed the off-label product use of ketamine in head injury; and he is supported by NIH grant DP2HD101400. Funding Information: Dr. Kochanek's institution received funding from the National Institutes of Health (NIH) and the U.S. Army; he received funding from lectures at national meetings and/or as a guest professor at various institutions of higher education and for editing or authoring books and/or chapters; and he disclosed that he has served as an expert witness on several cases over the past 36 months and has multiple patents. Dr. Herrmann's institution received funding from the NIH (T32 HD040686), the Safar Center for Resuscitation Research, the Zoll Foundation, and the Laerdal Foundation. Dr. Hermann received support for article research from the NIH. Dr. Bleck received funding from Marinus Pharmaceuticals and the American Board of Internal Medicine; he disclosed the off-label product use of ketamine in head injury; and he is supported by NIH grant DP2HD101400.
PY - 2023/5/1
Y1 - 2023/5/1
KW - cerebral blood flow
KW - children
KW - head trauma
KW - intracranial pressure
KW - seizure
KW - spreading depolarization
UR - http://www.scopus.com/inward/record.url?scp=85152600372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152600372&partnerID=8YFLogxK
U2 - 10.1097/CCM.0000000000005826
DO - 10.1097/CCM.0000000000005826
M3 - Editorial
C2 - 37052437
AN - SCOPUS:85152600372
SN - 0090-3493
VL - 51
SP - 677
EP - 680
JO - Critical Care Medicine
JF - Critical Care Medicine
IS - 5
ER -